



(11) **EP 3 854 885 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71, 72

(51) International Patent Classification (IPC):
C12Q 1/6883 (2018.01)

(52) Cooperative Patent Classification (CPC):
C12Q 1/6883; C12Q 2600/106; C12Q 2600/156

(48) Corrigendum issued on:
24.05.2023 Bulletin 2023/21

(86) International application number:
PCT/ES2019/070606

(43) Date of publication:
28.07.2021 Bulletin 2021/30

(87) International publication number:
WO 2020/058545 (26.03.2020 Gazette 2020/13)

(21) Application number: **19794171.9**

(22) Date of filing: **13.09.2019**

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **19.09.2018 EP 18195545**

(71) Applicants:
• **Canut Jordana, Maria Isabel**
08021 Barcelona (ES)
• **Casaroli Marano, Ricardo Pedro**
08021 Barcelona (ES)
• **Quantitative Genomic Medicine Laboratories,**
S.L.
08950 Esplugues de Llobregat (Barcelona) (ES)

(72) Inventors:
• **CANUT JORDANA, Maria Isabel**
08021 Barcelona (ES)
• **CASAROLI MARANO, Ricardo Pedro**
08021 Barcelona (ES)
• **ARMENGOL DULCET, Lluís**
08950 Esplugues de Llobregat (Barcelona) (ES)
• **VILLA MARCOS, Olaya**
08950 Esplugues de Llobregat (Barcelona) (ES)
• **BARRAQUER COMPTE, Rafael Ignacio**
08021 Barcelona (ES)

(74) Representative: **Durán-Corretjer, S.L.P.**
Còrsega, 329
(Paseo de Gracia/Diagonal)
08037 Barcelona (ES)

(54) **PHARMACOGENOMIC SCREENING METHOD FOR ANTICIPATING A PATIENT'S RESPONSE TO THE TREATMENT OF OCULAR HYPERTENSION**

(57) The present invention discloses a method for *in vitro* screening of a patient's response to the treatment of ocular hypertension, comprising the steps of: (a) obtaining a sample of a biological fluid from a patient; and (b) determining the number of copies of an intronic portion of gene MLIP (MLIP-AS1), wherein more than one copy

of said MLIP-AS1 is an indication that the patient is better responder to the treatment with prostaglandins, and wherein less than one copy of said MLIP-AS1 is an indication that the patient is responder to the treatment with β -blockers.

EP 3 854 885 A8